137 related articles for article (PubMed ID: 38569830)
1. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Clinical course of cervical intraepithelial neoplasia grade 2: a population-based cohort study.
Lycke KD; Kahlert J; Damgaard RK; Eriksen DO; Bennetsen MH; Gravitt PE; Petersen LK; Hammer A
Am J Obstet Gynecol; 2023 Dec; 229(6):656.e1-656.e15. PubMed ID: 37595822
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus vaccination history and diagnosis of cervical intraepithelial neoplasia grade ≥2 severe lesions among a cohort of women who underwent colposcopy in Kaiser Permanente Southern California.
Lonky NM; Xu L; Da Silva DM; Felix JC; Chao C
Am J Obstet Gynecol; 2021 Dec; 225(6):656.e1-656.e11. PubMed ID: 34273278
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus genotypes and risk of persistence and progression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2.
Damgaard RK; Jenkins D; Stoler MH; de Koning M; van de Sandt M; Lycke KD; Kahlert J; Gravitt PE; Quint WGV; Steiniche T; Petersen LK; Hammer A
Am J Obstet Gynecol; 2024 Feb; ():. PubMed ID: 38336125
[TBL] [Abstract][Full Text] [Related]
6. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
7. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
8. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of HPV vaccination against cervical neoplasia among birth cohorts ineligible for routine vaccination.
Dong L; Nygård M; Støer NC; Klungsøyr O; Hansen BT
Int J Cancer; 2023 Jul; 153(2):399-406. PubMed ID: 36866965
[TBL] [Abstract][Full Text] [Related]
12. Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease-a 16-year follow-up study.
Alder S; Megyessi D; Sundström K; Östensson E; Mints M; Belkić K; Arbyn M; Andersson S
Am J Obstet Gynecol; 2020 Feb; 222(2):172.e1-172.e12. PubMed ID: 31473226
[TBL] [Abstract][Full Text] [Related]
13. Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center.
Domröse CM; Wieland U; Pilch H; Einzmann T; Schömig-Markiefka B; Mallmann P; Silling S; Mallmann MR
J Low Genit Tract Dis; 2022 Apr; 26(2):122-126. PubMed ID: 35019900
[TBL] [Abstract][Full Text] [Related]
14. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
15. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK
Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217
[TBL] [Abstract][Full Text] [Related]
16. The 5-year risk of recurrence of grade 2/3 cervical intraepithelial neoplasia after treatment in a population screening programme by human papillomavirus status: A cohort study in central Italy.
Visioli CB; Iossa A; Gorini G; Mantellini P; Lelli L; Auzzi N; Pierro CD; Carozzi FM; Zappa M
J Med Screen; 2023 Dec; 30(4):191-200. PubMed ID: 37229655
[TBL] [Abstract][Full Text] [Related]
17. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study.
Verdoodt F; Dehlendorff C; Kjaer SK
Clin Infect Dis; 2020 Feb; 70(4):608-614. PubMed ID: 30892587
[TBL] [Abstract][Full Text] [Related]
18. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial comparing cervical dysplasia treatment with cryotherapy vs loop electrosurgical excision procedure in HIV-seropositive women from Johannesburg, South Africa.
Smith JS; Sanusi B; Swarts A; Faesen M; Levin S; Goeieman B; Ramotshela S; Rakhombe N; Williamson AL; Michelow P; Omar T; Hudgens MG; Firnhaber C
Am J Obstet Gynecol; 2017 Aug; 217(2):183.e1-183.e11. PubMed ID: 28366730
[TBL] [Abstract][Full Text] [Related]
20. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial.
Elfgren K; Elfström KM; Naucler P; Arnheim-Dahlström L; Dillner J
Am J Obstet Gynecol; 2017 Mar; 216(3):264.e1-264.e7. PubMed ID: 27825977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
